Document is current
Any future updates will be listed below
-
Authors
Plaza-Clar, Roger https://orcid.org/0009-0005-1913-3545
Weber, Maximilian
Kadam, Vaibhavi
Deuschle, Christian
Ma, Yihua
Farris, Carly M.
Concha-Marambio, Luis
Mengel, David
Rossi, Marcello
Mammana, Angela
Parchi, Piero
Synofzik, Matthis
Brockmann, Kathrin
Gasser, Thomas
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research (022411)
Ministero della Salute (RF-2021-12374386)
Else Kröner-Fresenius-Stiftung; European Union, project European 334 Rare Disease Research Alliance (101156595)
- License Information
-
More Information
Article History
Received: 4 March 2026
Accepted: 11 May 2026
First Online: 27 May 2026
Declarations
:
: Thomas Gasser has received research support from the German Research Foundation (DFG), the German Ministry of Research (BMBF), the European Commission, the Michael J Fox Foundation, Chem Div. Inc, and the Charitable Hertie Foundation. He has received speaker’s honoraria from UCB Pharma, Novartis, Sanofi, BIAL and MedUpdate and consulting fees from Bayer AG, Blue Rock Therapeutics and Coave Therapeutics, Ono Pharmaceutical, Lilly Deutschland GmbH, Roche Pharma AG, BIAL, Biogen MA Inc. and SciNeuro Therapeutics. Kathrin Brockmann has received research funding from the Michael J. Fox Foundation for Parkinson’s Research, the German Society for Parkinson DPG, the Health Forum Baden Wuerttemberg, the Else Kröner-Fresenius-Stiftung, the University of Tuebingen, and from the German Research Foundation DFG. Kathrin Brockmann is a consultant for F. Hoffmann-La Roche Ltd., Vanqua Bio, and the Michael J. Fox Foundation for Parkinson’s Research and has received speaker honoraria from Abbvie, Lundbeck, UCB and Zambon. Matthis Synofzik has received consultancy honoraria from UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly, Quince, Neurocrine, Insmed, and Solaxa, all unrelated to the present manuscript. Luis Concha-Marambio, Yihua Ma, and Carly M Farris are employees of Amprion and declares employee stock option ownership and invention of patents related to SAA technology assigned to Amprion. Roger Plaza-Clar, Maximilian Weber, Vaibhavi Kadam, Christian Deuschle, David Mengel, Marcello Rossi, Angela Mammana, Piero Parchi, have nothing to disclose.
: The study was approved by the Ethics Committee of the University of Tuebingen (353/2022BO2). All participants gave written informed consent for participation in the study and for the use and publication of their anonymized data. This study was conducted in accordance with the principles of the Declaration of Helsinki.
